Incyte Corporation (INCY) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Wilmington, DE, United States. Der aktuelle CEO ist William J. Meury.
INCY hat IPO-Datum 1993-11-04, 2,617 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $19.44B.
Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes innovative therapies for oncology and inflammatory diseases in the United States and internationally. The company's commercial portfolio includes JAKAFI for myelofibrosis and polycythemia vera, PEMAZYRE for fibroblast growth factor receptor-driven cancers, and ICLUSIG for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Its pipeline comprises multiple clinical-stage candidates, including ruxolitinib for steroid-refractory chronic graft-versus-host disease, pemigatinib for various solid tumors, and Retifanlimab for MSI-high cancers and non-small cell lung cancer. The company maintains strategic partnerships with major pharmaceutical firms including Novartis, Eli Lilly, and others to accelerate development of combination therapies and novel treatment approaches. Founded in 1991 and headquartered in Wilmington, Delaware, Incyte focuses on addressing significant unmet medical needs in oncology and immunology.
